Mer­ck­'s $500M bet on Sin­ga­pore leads to new man­u­fac­tur­ing sites mak­ing Keytru­da, Gar­dasil and fu­ture in­halers

In a boost to its Asia Pa­cif­ic re­gion­al head­quar­ters in Sin­ga­pore, Mer­ck has opened a new sec­ondary pack­ag­ing fa­cil­i­ty and bro­ken ground on a sep­a­rate fa­cil­i­ty that will man­u­fac­ture next-gen­er­a­tion in­halers.

The two man­u­fac­tur­ing sites are part of a $500 mil­lion in­vest­ment to ex­pand pro­duc­tion of med­i­cines and vac­cines in Sin­ga­pore over five years, dat­ing back to 2020.

As Fer­nan­do Otero, as­so­ciate vice pres­i­dent, MSD Man­u­fac­tur­ing Di­vi­sion, Sin­ga­pore, put it, Mer­ck sees the coun­try “as a strate­gic node in our com­pa­ny’s glob­al man­u­fac­tur­ing net­work with a fo­cus on pro­duc­ing in­no­v­a­tive med­i­cines to treat chron­ic dis­eases and can­cer as well as vac­cines that pre­vent in­fec­tious dis­eases for pa­tients liv­ing in Sin­ga­pore and through­out the Asia Pa­cif­ic re­gion and be­yond.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.